Aroa Biosurgery Limited Stock

Equities

ARX

NZARXE0001S1

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. 02:10:44 2024-04-26 am EDT 5-day change 1st Jan Change
0.51 AUD +2.00% Intraday chart for Aroa Biosurgery Limited +2.00% -38.55%

Financials

Sales 2024 * 67.78M 40.21M 61.53M Sales 2025 * 87.08M 51.67M 79.06M Capitalization 193M 115M 175M
Net income 2024 * -6M -3.56M -5.45M Net income 2025 * 2M 1.19M 1.82M EV / Sales 2024 * 2.46 x
Net cash position 2024 * 26.56M 15.76M 24.12M Net cash position 2025 * 28.87M 17.13M 26.21M EV / Sales 2025 * 1.89 x
P/E ratio 2024 *
-25.9 x
P/E ratio 2025 *
82.6 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 73.03%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.00%
1 week+2.00%
Current month-8.11%
1 month-9.73%
3 months-30.14%
6 months-32.67%
Current year-38.55%
More quotes
1 week
0.48
Extreme 0.475
0.54
1 month
0.48
Extreme 0.475
0.59
Current year
0.48
Extreme 0.475
0.87
1 year
0.48
Extreme 0.475
1.09
3 years
0.48
Extreme 0.475
1.30
5 years
0.48
Extreme 0.475
1.75
10 years
0.48
Extreme 0.475
1.75
More quotes
Date Price Change Volume
24-04-26 0.51 +2.00% 103,768
24-04-24 0.5 -0.99% 119,730
24-04-23 0.505 +1.00% 340,841
24-04-22 0.5 0.00% 324,654
24-04-19 0.5 -1.96% 546,424

Delayed Quote Australian S.E., April 26, 2024 at 02:10 am EDT

More quotes
Aroa Biosurgery Limited is a soft-tissue regeneration company. It develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that is the building block for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM for soft tissue repair, reinforcement and complex wounds. Its subsidiaries are Aroa Biosurgery Incorporated and Mesynthes Nominee Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.5609 NZD
Average target price
1.105 NZD
Spread / Average Target
+97.06%
Consensus

Quarterly revenue - Rate of surprise